Back to news

Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire•19/11/2026•16:10 ET
0

Key Highlights

  • ➤Azora Therapeutics (AZR) grants 40,000-share inducement option to one new employee
  • ➤$3.81 exercise price matches Azora’s November 16 closing stock price
  • ➤Option vests over four years and expires after ten years

LOS ANGELES, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Azora Therapeutics, Inc. (NASDAQ: AZR) (the “Company”), a biopharmaceutical company developing treatments for serious inflammatory diseases, announced today that the Compensation Committee of its Board of Directors granted an option to purchase 40,000 shares of the Company’s common stock under the Azora Therapeutics, Inc. 2026 Employment Inducement Equity Incentive Plan (the “2026 Inducement Plan”) to one new non-executive employee as an inducement material to such person entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The option award has an exercise price of $3.81 per share, the closing price of the Company’s common stock on November 16, 2026, the effective date of grant, and has a ten-year term. The option award will vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments thereafter, subject to the recipient’s continued service through each applicable vesting date. The option award is subject to the terms and conditions of the 2026 Inducement Plan and the terms and conditions of an option award agreement covering the grant.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in